TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Postmenopausal Vaginal Atrophy Drugs Market, Global Outlook and Forecast 2023-2029

Postmenopausal Vaginal Atrophy Drugs Market, Global Outlook and Forecast 2023-2029

  • Category:Life Sciences
  • Published on : 03 June 2023
  • Pages :79
  • Formats:
  • Report Code:SMR-7703003
OfferClick for best price

Best Price: $2600

Postmenopausal Vaginal Atrophy Drugs Market Size, Share 2023


Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.

This report aims to provide a comprehensive presentation of the global market for Postmenopausal Vaginal Atrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Postmenopausal Vaginal Atrophy Drugs. This report contains market size and forecasts of Postmenopausal Vaginal Atrophy Drugs in global, including the following market information:

Global Postmenopausal Vaginal Atrophy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global Postmenopausal Vaginal Atrophy Drugs Market Sales, 2018-2023, 2024-2029, (K Units)

Global top five Postmenopausal Vaginal Atrophy Drugs companies in 2022 (%)

The global Postmenopausal Vaginal Atrophy Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.

Vaginal Gels Segment to Reach $ Million by 2029, with a % CAGR in next six years.

The global key manufacturers of Postmenopausal Vaginal Atrophy Drugs include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company and Allergan plc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.

We surveyed the Postmenopausal Vaginal Atrophy Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Postmenopausal Vaginal Atrophy Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Type, 2022 (%)

Vaginal Gels

Creams

Tablets

Rings

Patches

Global Postmenopausal Vaginal Atrophy Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, by Application, 2022 (%)

Offline Stores

Online Stores

Global Postmenopausal Vaginal Atrophy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global Postmenopausal Vaginal Atrophy Drugs Market Segment Percentages, By Region and Country, 2022 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Postmenopausal Vaginal Atrophy Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)

Key companies Postmenopausal Vaginal Atrophy Drugs revenues share in global market, 2022 (%)

Key companies Postmenopausal Vaginal Atrophy Drugs sales in global market, 2018-2023 (Estimated), (K Units)

Key companies Postmenopausal Vaginal Atrophy Drugs sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

Actavis plc

Bionovo, Inc.

Endoceutics, Inc.

Novo Nordisk A/S

Pfizer Inc.

Teva Pharmaceuticals Ltd.

Therapeutics MD, Inc.

Shionogi & Company

Allergan plc

Shionogi & Co. Ltd.

Outline of Major Chapters:

Chapter 1: Introduces the definition of Postmenopausal Vaginal Atrophy Drugs, market overview.

Chapter 2: Global Postmenopausal Vaginal Atrophy Drugs market size in revenue and volume.

Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Postmenopausal Vaginal Atrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Global Postmenopausal Vaginal Atrophy Drugs capacity by region & country.

Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 11: The main points and conclusions of the report.

Report Attributes Report Details
Report Title Postmenopausal Vaginal Atrophy Drugs Market, Global Outlook and Forecast 2023-2029
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2022
Forecast Year 2030
Number of Pages 79 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Postmenopausal Vaginal Atrophy Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Postmenopausal Vaginal Atrophy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Postmenopausal Vaginal Atrophy Drugs Overall Market Size
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size: 2022 VS 2029
2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Postmenopausal Vaginal Atrophy Drugs Players in Global Market
3.2 Top Global Postmenopausal Vaginal Atrophy Drugs Companies Ranked by Revenue
3.3 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Companies
3.4 Global Postmenopausal Vaginal Atrophy Drugs Sales by Companies
3.5 Global Postmenopausal Vaginal Atrophy Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Postmenopausal Vaginal Atrophy Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Players in Global Market
3.8.1 List of Global Tier 1 Postmenopausal Vaginal Atrophy Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Market Size Markets, 2022 & 2029
4.1.2 Vaginal Gels
4.1.3 Creams
4.1.4 Tablets
4.1.5 Rings
4.1.6 Patches
4.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
4.2.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2023
4.2.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2024-2029
4.2.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
4.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
4.3.1 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2023
4.3.2 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2024-2029
4.3.3 By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
4.4 By Type - Global Postmenopausal Vaginal Atrophy Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2022 & 2029
5.1.2 Offline Stores
5.1.3 Online Stores
5.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
5.2.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2023
5.2.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2024-2029
5.2.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
5.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
5.3.1 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2023
5.3.2 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2024-2029
5.3.3 By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
5.4 By Application - Global Postmenopausal Vaginal Atrophy Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Market Size, 2022 & 2029
6.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue & Forecasts
6.2.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2023
6.2.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2024-2029
6.2.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
6.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales & Forecasts
6.3.1 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2023
6.3.2 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales, 2024-2029
6.3.3 By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029
6.4.2 By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2029
6.4.3 US Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.4.4 Canada Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.4.5 Mexico Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029
6.5.2 By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2029
6.5.3 Germany Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.4 France Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.5 U.K. Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.6 Italy Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.7 Russia Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.5.9 Benelux Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029
6.6.2 By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2029
6.6.3 China Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.6.4 Japan Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.6.5 South Korea Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.6.7 India Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029
6.7.2 By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2029
6.7.3 Brazil Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.7.4 Argentina Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, 2018-2029
6.8.3 Turkey Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.8.4 Israel Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
6.8.6 UAE Postmenopausal Vaginal Atrophy Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Actavis plc
7.1.1 Actavis plc Company Summary
7.1.2 Actavis plc Business Overview
7.1.3 Actavis plc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Actavis plc Key News & Latest Developments
7.2 Bionovo, Inc.
7.2.1 Bionovo, Inc. Company Summary
7.2.2 Bionovo, Inc. Business Overview
7.2.3 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Bionovo, Inc. Key News & Latest Developments
7.3 Endoceutics, Inc.
7.3.1 Endoceutics, Inc. Company Summary
7.3.2 Endoceutics, Inc. Business Overview
7.3.3 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Endoceutics, Inc. Key News & Latest Developments
7.4 Novo Nordisk A/S
7.4.1 Novo Nordisk A/S Company Summary
7.4.2 Novo Nordisk A/S Business Overview
7.4.3 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Novo Nordisk A/S Key News & Latest Developments
7.5 Pfizer Inc.
7.5.1 Pfizer Inc. Company Summary
7.5.2 Pfizer Inc. Business Overview
7.5.3 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Pfizer Inc. Key News & Latest Developments
7.6 Teva Pharmaceuticals Ltd.
7.6.1 Teva Pharmaceuticals Ltd. Company Summary
7.6.2 Teva Pharmaceuticals Ltd. Business Overview
7.6.3 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Teva Pharmaceuticals Ltd. Key News & Latest Developments
7.7 Therapeutics MD, Inc.
7.7.1 Therapeutics MD, Inc. Company Summary
7.7.2 Therapeutics MD, Inc. Business Overview
7.7.3 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Therapeutics MD, Inc. Key News & Latest Developments
7.8 Shionogi & Company
7.8.1 Shionogi & Company Company Summary
7.8.2 Shionogi & Company Business Overview
7.8.3 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Shionogi & Company Key News & Latest Developments
7.9 Allergan plc
7.9.1 Allergan plc Company Summary
7.9.2 Allergan plc Business Overview
7.9.3 Allergan plc Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Allergan plc Key News & Latest Developments
7.10 Shionogi & Co. Ltd.
7.10.1 Shionogi & Co. Ltd. Company Summary
7.10.2 Shionogi & Co. Ltd. Business Overview
7.10.3 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Major Product Offerings
7.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Shionogi & Co. Ltd. Key News & Latest Developments
8 Global Postmenopausal Vaginal Atrophy Drugs Production Capacity, Analysis
8.1 Global Postmenopausal Vaginal Atrophy Drugs Production Capacity, 2018-2029
8.2 Postmenopausal Vaginal Atrophy Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Postmenopausal Vaginal Atrophy Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Postmenopausal Vaginal Atrophy Drugs Supply Chain Analysis
10.1 Postmenopausal Vaginal Atrophy Drugs Industry Value Chain
10.2 Postmenopausal Vaginal Atrophy Drugs Upstream Market
10.3 Postmenopausal Vaginal Atrophy Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Postmenopausal Vaginal Atrophy Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Key Players of Postmenopausal Vaginal Atrophy Drugs in Global Market
Table 2. Top Postmenopausal Vaginal Atrophy Drugs Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Companies, 2018-2023
Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales by Companies, (K Units), 2018-2023
Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 9. List of Global Tier 1 Postmenopausal Vaginal Atrophy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Postmenopausal Vaginal Atrophy Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2018-2023
Table 15. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2024-2029
Table 16. By Application ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2018-2023
Table 20. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2024-2029
Table 21. By Region ? Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2018-2023
Table 25. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales (K Units), 2024-2029
Table 26. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2018-2023
Table 29. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2024-2029
Table 30. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2018-2023
Table 33. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2024-2029
Table 34. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2018-2023
Table 37. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2024-2029
Table 38. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2018-2023
Table 41. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales, (K Units), 2024-2029
Table 46. Actavis plc Company Summary
Table 47. Actavis plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 48. Actavis plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Actavis plc Key News & Latest Developments
Table 50. Bionovo, Inc. Company Summary
Table 51. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 52. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Bionovo, Inc. Key News & Latest Developments
Table 54. Endoceutics, Inc. Company Summary
Table 55. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 56. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Endoceutics, Inc. Key News & Latest Developments
Table 58. Novo Nordisk A/S Company Summary
Table 59. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 60. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novo Nordisk A/S Key News & Latest Developments
Table 62. Pfizer Inc. Company Summary
Table 63. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 64. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Pfizer Inc. Key News & Latest Developments
Table 66. Teva Pharmaceuticals Ltd. Company Summary
Table 67. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 68. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Teva Pharmaceuticals Ltd. Key News & Latest Developments
Table 70. Therapeutics MD, Inc. Company Summary
Table 71. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 72. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Therapeutics MD, Inc. Key News & Latest Developments
Table 74. Shionogi & Company Company Summary
Table 75. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 76. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Shionogi & Company Key News & Latest Developments
Table 78. Allergan plc Company Summary
Table 79. Allergan plc Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 80. Allergan plc Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. Allergan plc Key News & Latest Developments
Table 82. Shionogi & Co. Ltd. Company Summary
Table 83. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Product Offerings
Table 84. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Shionogi & Co. Ltd. Key News & Latest Developments
Table 86. Postmenopausal Vaginal Atrophy Drugs Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Postmenopausal Vaginal Atrophy Drugs Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Postmenopausal Vaginal Atrophy Drugs Production by Region, 2018-2023 (K Units)
Table 89. Global Postmenopausal Vaginal Atrophy Drugs Production by Region, 2024-2029 (K Units)
Table 90. Postmenopausal Vaginal Atrophy Drugs Market Opportunities & Trends in Global Market
Table 91. Postmenopausal Vaginal Atrophy Drugs Market Drivers in Global Market
Table 92. Postmenopausal Vaginal Atrophy Drugs Market Restraints in Global Market
Table 93. Postmenopausal Vaginal Atrophy Drugs Raw Materials
Table 94. Postmenopausal Vaginal Atrophy Drugs Raw Materials Suppliers in Global Market
Table 95. Typical Postmenopausal Vaginal Atrophy Drugs Downstream
Table 96. Postmenopausal Vaginal Atrophy Drugs Downstream Clients in Global Market
Table 97. Postmenopausal Vaginal Atrophy Drugs Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Postmenopausal Vaginal Atrophy Drugs Segment by Type in 2022
Figure 2. Postmenopausal Vaginal Atrophy Drugs Segment by Application in 2022
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Postmenopausal Vaginal Atrophy Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Postmenopausal Vaginal Atrophy Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. Postmenopausal Vaginal Atrophy Drugs Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2022
Figure 9. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 11. By Type - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 12. By Type - Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 15. By Application - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 16. By Application - Global Postmenopausal Vaginal Atrophy Drugs Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 20. By Region - Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 21. By Country - North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 22. By Country - North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 23. US Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 28. Germany Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. France Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 37. China Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. India Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 43. By Country - South America Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 44. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share, 2018-2029
Figure 48. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Postmenopausal Vaginal Atrophy Drugs Revenue, (US$, Mn), 2018-2029
Figure 52. Global Postmenopausal Vaginal Atrophy Drugs Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Postmenopausal Vaginal Atrophy Drugs by Region, 2022 VS 2029
Figure 54. Postmenopausal Vaginal Atrophy Drugs Industry Value Chain
Figure 55. Marketing Channels

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount